A Highly Potent and Selective
KAT6A Degrader
This Degrader Demonstrates Robust Anti-tumor Activity With A Low Risk Of Hematotoxicity In Preclinical Studies
A Novel, Potent, and Selective
Orally Active MRGPRX2 Antagonist
Atheron Discovered This Small Molecule For The Potential Treatment Of Mast Cell-mediated Disorders,Targeting A Receptor That Mediates IgE-independent Degranulation.
A Novel, and Highly Selective
ITK Inhibitor
This Inhibitor Selectively Blocks ITK Activity, Sparing RLK, and Demonstrates Robust Efficacy in Preclinical Models, Suggesting a Potential Novel Therapeutic Strategy for Atopic Dermatitis.
